Fly News Breaks for November 10, 2019
Nov 10, 2019 | 20:17 EDT
Piper Jaffray analyst Joseph Catanzaro reiterated an Overweight rating and $30 price target on Iovance following the company's update for cohort 2 of melanoma's lifileucel study at SITC. The analyst said that even a worst case scenario on the data "points to an eventual very favorable mDOR for cohort 2." Catanzaro reiterated that he believes "this has implications around commercial adoption and peak penetration if replicated in cohort 4," which is projected to complete enrollment in the Q1 of 2020, with a regulatory filing in late 2020.
News For IOVA From the Last 2 Days
There are no results for your query IOVA